Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Opinion and Evidence in Cancer

Opinion and Evidence in Cancer reality in the clinic. Of note, are the exciting results shown recently using targeted molecular therapies. To help you keep up-to-date with the latest advances worldwide on all aspects of drug therapy and management of cancer, this section of the journal brings you information selected from the drug therapy reporting service Inpharma Weekly . Each issue contains easy-to-read summaries of the most important research and development news, clinical studies, treatment guidelines, pharmacoeconomic and adverse reaction news, and expert opinion pieces published in the world’s top oncology publications. 1 Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected form over 1600 biomedical journals, this newsletter is produced by Adis International and is available in a variety of formats. Please contact your nearest Adis office for subscription details. 224 Opinion and Evidence in Cancer 1. Imatinib Mesylate Therapy Reviewed 2. Clinical Success with p53 Gene Therapy Still a Possibility Imatinib mesylate (STI571), a selective inhibitor of the The p53 gene, involved in tumor suppression and frequently BCR-ABL tyrosine kinase, has demonstrated ‘extraordinary ac- inactivated in human malignancies, may still present a viable tivity’ in chronic myeloid leukemia (CML) and gastrointestinal target for gene therapy strategies http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Opinion and Evidence in Cancer

American Journal of Cancer , Volume 1 (3) – Aug 9, 2012

Loading next page...
 
/lp/springer-journals/opinion-and-evidence-in-cancer-NpRDXjkgex
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201030-00007
Publisher site
See Article on Publisher Site

Abstract

reality in the clinic. Of note, are the exciting results shown recently using targeted molecular therapies. To help you keep up-to-date with the latest advances worldwide on all aspects of drug therapy and management of cancer, this section of the journal brings you information selected from the drug therapy reporting service Inpharma Weekly . Each issue contains easy-to-read summaries of the most important research and development news, clinical studies, treatment guidelines, pharmacoeconomic and adverse reaction news, and expert opinion pieces published in the world’s top oncology publications. 1 Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected form over 1600 biomedical journals, this newsletter is produced by Adis International and is available in a variety of formats. Please contact your nearest Adis office for subscription details. 224 Opinion and Evidence in Cancer 1. Imatinib Mesylate Therapy Reviewed 2. Clinical Success with p53 Gene Therapy Still a Possibility Imatinib mesylate (STI571), a selective inhibitor of the The p53 gene, involved in tumor suppression and frequently BCR-ABL tyrosine kinase, has demonstrated ‘extraordinary ac- inactivated in human malignancies, may still present a viable tivity’ in chronic myeloid leukemia (CML) and gastrointestinal target for gene therapy strategies

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

There are no references for this article.